-
ESUI: Getting ready for the new EU approach to PCa screening
November 2, 2023This year, the annual EAU Section of Urological Imaging (ESUI) meeting has been integrated into the 15th European Multidisciplinary...
00 -
Diagnosing PCa – what’s the best option?
November 11, 2022The objective of the 14th European Multidisciplinary Congress on Urological Cancers is to work together to achieve the best...
-
EMUC22: Relevant topics and Prof. Stenzl’s personal highlights
June 27, 2022Year after year since 2008, the European Multidisciplinary Congress on Urological Cancers (EMUC) provides the urological community with integrative...
-
Personalised approaches to treating GU cancers
November 27, 2021Personalised approaches such as the use of circulating tumour DNA (ctDNA) biomarkers and genetic testing is the way to...
-
Strengths and limitations of PSMA PET: When to use it (and when not to)
November 26, 2021The prostate-specific membrane antigen positron emission tomography (PSMA PET) scan is the (relatively) new kid on the block in...
-
Radioligand therapy: multidisciplinary collaboration for health system readiness
September 13, 2021By the European Society for Medical Oncology (ESMO) team Join the EMUC21 session ‘Radioligand therapy: multidisciplinary collaboration for health...
-
EMUC20: Highlights in GU cancers
November 13, 2020Active surveillance should be considered the first treatment for prostate cancer in order to ensure the best quality of...
-
Early detection of prostate cancer: a multidisciplinary look
November 15, 2019Using the fortieth anniversary of the discovery of PSA as a starting point, EMUC19 began with a session on...
-
The future of good evidence gathering for PCa
November 9, 2018New approaches to clinical trials can lead to more successful results in the challenging near future. Parallel, comparative studies...
-
PCa management essentials opens EMUC’s 10th year
November 9, 2018Throughout a decade, the European Multidisciplinary Congress on Urological Cancers (EMUC) has established its reputation as the leading platform...
